ni Ronalyn Seminiano Reonico | May 8, 2021
Inaprubahan na ng World Health Organization (WHO) ang emergency use ng Sinopharm COVID-19 vaccine ng China noong Biyernes.
Ito ang kauna-unahang Chinese vaccine na binigyan ng WHO ng emergency use approval laban sa infectious disease.
Pahayag ni WHO Director-General Tedros Adhanom Ghebreyesus, "This expands the list of COVID-19 vaccines that COVAX can buy, and gives countries confidence to expedite their own regulatory approval, and to import and administer a vaccine."
Kabilang din sa mga COVID-19 vaccines na nakatanggap na ng emergency approval ng WHO ay ang Pfizer-BioNTech, AstraZeneca, Johnson & Johnson, at Moderna.
Noong April 26 nagkaroon ng pagpupulong ang technical advisory group ng WHO kung saan ni-review ang clinical data at manufacturing practices ng Sinopharm.
Saad pa ng WHO, "Its easy storage requirements make it highly suitable for low-resource settings.”
Ayon kay Tedros, inirekomenda naman ng Strategic Advisory Group of Experts (SAGE) ang pagbabakuna ng two doses ng Sinopharm sa mga edad 18 pataas.
Saad ng WHO, "On the basis of all available evidence, WHO recommends the vaccine for adults 18 years and older, in a two-dose schedule with a spacing of three to four weeks."
Tinatayang aabot naman sa 79% ang efficacy rate ng Sinopharm na dinevelop ng Beijing Biological Products Institute.
Samantala, pahayag din ng WHO, "Few older adults (over 60 years) were enrolled in clinical trials, so efficacy could not be estimated in this age group."
Noong Miyerkules naman, nagsagawa ng review ang mga eksperto ng WHO sa Sinovac Biotech na gawa rin ng China.
Pahayag ni WHO Technical Advisory Group Chair Arnaud Didierlaurent, "We have started to review the report from Sinovac. We actually requested additional information to the manufacturer... which we hope to receive very soon to make a decision."